We thus explored whether LIPA polymorphisms were associated with other metabolic cardiovascular risk factors, finding that these polymorphisms were significantly associated with hypo-α-lipoproteinemia, hypercholesterolemia, hypertriglyceridemia, metabolic syndrome, and type 2 diabetes mellitus in premature CAD patients. Here, LIPA is linked to metabolic syndrome.